Nanotechnology for neurodegenerative disorders

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 8, Issue SUPPL. 1, 2012, Pages

  Re, Francesca ^a   Gregori, Maria ^a   Masserini, Massimo ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Blood brain barrier; Brain; Nanomaterials; Nanoparticles; Neurodegenerative disorders

Indexed keywords

BLOOD-BRAIN BARRIER; CELLULAR UPTAKE; COMPLEX PROBLEMS; DIAGNOSTIC IMAGING; ENGINEERED NANOMATERIALS; IMAGING AGENT; MULTI-FUNCTIONALIZATION; NEURODEGENERATIVE DISORDERS; NEURONAL TISSUES; NEUROPROTECTION; NEUROTOXICITY; PHYSICO-CHEMICALS; TARGET ORGANS;

BLOOD; BRAIN; ENDOTHELIAL CELLS; NANOPARTICLES; NANOSTRUCTURED MATERIALS; TISSUE;

NEURODEGENERATIVE DISEASES;

AMYLOID BETA MONOCLONAL ANTIBODY; CARBON NANOTUBE; DENDRIMER; DOPAMINE; GOLD NANOPARTICLE; IRON OXIDE NANOPARTICLE; LIPOSOME; MONOCLONAL ANTIBODY; NANOGEL; NANOPARTICLE; QUANTUM DOT; RILUZOLE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TACRINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; DEGENERATIVE DISEASE; HUMAN; NANOTECHNOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PRION DISEASE; REVIEW; TISSUE REGENERATION; TRANSCYTOSIS;

ANIMALS; BRAIN; DRUG DELIVERY SYSTEMS; HUMANS; NANOMEDICINE; NANOSTRUCTURES; NANOTECHNOLOGY; NEURODEGENERATIVE DISEASES;

EID: 84865599063     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2012.05.007     Document Type: Review

References (54)

1. Gabathuler R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol Dis 2010, 37:48-57.
2. Fernandes C., Soni U., Patravale V. Nano-interventions for neurodegenerative disorders. Pharmacol Res 2010, 62:166-178.
3. Abbott N.J., Chugani D.C., Zaharchuk G., Rosen B.R., Lo E.H. Delivery of imaging agents into brain. Adv Drug Deliv Rev 1999, 37:253-277.
4. Patel M.M., Goyal B.R., Bhadada S.V., Bhatt J.S., Amin A.F. Getting into the brain: approaches to enhance brain drug delivery. CNS Drugs 2009, 23:35-58.
5. Bhaskar S., Tian F., Stoeger T., et al. Multifunctional nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging. Part Fibre Toxicol 2010, 7:3.
6. Kim H.R., Andrieux K., Gil S., et al. Translocation of poly(ethylene glycol-co-hexadecyl)cyanoacrylate nanoparticles into rat brain endothelial cells: role of apolipoproteins in receptor-mediated endocytosis. Biomacromolecules 2007, 8:793-799.
7. Ulbrich K., Hekmatara T., Herbert E., Kreuter J. Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur J Pharm Biopharm 2009, 71:251-256.
8. Boado R.J. A new generation of neurobiological drugs engineered to overcome the challenges of brain drug delivery. Drug News Perspect 2008, 21:489-503.
9. Ittner L.M., Götz J. Amyloid-β and tau-a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci 2011, 12:65-72.
10. Matsuoka Y., Saito M., LaFrancois J., et al. Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J Neurosci 2003, 23:29-33.
11. Gobbi M., Re F., Canovi M., et al. Lipid-based nanoparticles with high binding affinity for amyloid-beta1-42 peptide. Biomaterials 2010, 31:6519-6529.
12. Bereczki E., Re F., Masserini M.E., Winblad B., Pei J.J. Liposomes functionalized with acidic lipids rescue Aβ-induced toxicity in murine neuroblastoma cells. Nanomedicine 2011, 7:560-571.
13. Canovi M., Markoutsa E., Lazar A.N., et al. The binding affinity of anti-Aβ1-42 MAb-decorated nanoliposomes to Aβ1-42 peptides in vitro and to amyloid deposits in post-mortem tissue. Biomaterials 2011, 32:5489-5497.
14. Mourtas S., Canovi M., Zona C., et al. Curcumin-decorated nanoliposomes with very high affinity for amyloid-β1-42 peptide. Biomaterials 2011, 32:1635-1645.
15. Taylor M., Moore S., Mourtas S., et al. Effect of curcumin-associated and lipid ligand-functionalized nanoliposomes on aggregation of the Alzheimer's Aβ peptide. Nanomedicine 2011, 7:541-550.
16. Podolski I.Y., Podlubnaya Z.A., Kosenko E.A., et al. Effects of hydrated forms of C60 fullerene on amyloid 1-peptide fibrillization in vitro and performance of the cognitive task. J Nanosci Nanotechnol 2007, 7:1479-1485.
17. Liu G., Men P., Perry G., Smith M.A. Chapter 5 - Development of iron chelator-nanoparticle conjugates as potential therapeutic agents for Alzheimer disease. Prog Brain Res 2009, 180:97-108.
18. Liu G., Men P., Kudo W., Perry G., Smith M.A. Nanoparticle-chelator conjugates as inhibitors of amyloid-β aggregation and neurotoxicity: a novel therapeutic approach for Alzheimer disease. Neurosci Lett 2009, 455:187-190.
19. Wilson B., Samanta M.K., Santhi K., Kumar K.P., Paramakrishnan N., Suresh B. Targeted delivery of tacrine into the brain with polysorbate 80-coated poly(n-butylcyanoacrylate) nanoparticles. Eur J Pharm Biopharm 2008, 70:75-84.
20. Georganopoulou D.G., Chang L., Nam J.M., et al. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci USA 2005, 102:2273-2276.
21. Neely A., Perry C., Varisli B., et al. Ultrasensitive and highly selective detection of Alzheimer's disease biomarker using two-photon Rayleigh scattering properties of Au nanoparticle. ACS Nano 2009, 3:2834-2840.
22. Kosicek M., Kirsch S., Bene R., et al. Nano-HPLC-MS analysis of phospholipids in cerebrospinal fluid of Alzheimer's disease patients-a pilot study. Anal Bioanal Chem 2010, 398:2929-2937.
23. Feng L., Li S., Xiao B., Chen S., Liu R., Zhang Y. Fluorescence imaging of APP in Alzheimer's disease with quantum dot or Cy3: a comparative study. J Cent South Univ 2010, 35:903-909.
24. Yang J., Wadghiri Y.Z., Hoang D.M., et al. Detection of amyloid plaques targeted by USPIO-Aβ1-42 in Alzheimer's disease transgenic mice using magnetic resonance microimaging. Neuroimage 2011, 55:1600-1609.
25. Roney C.A., Arora V., Kulkarni P.V., Antich P.P., Bonte F.J. Nanoparticulate radiolabelled quinolines detect amyloid plaques in mouse models of Alzheimer's disease. Int J Alzheimer Dis 2010, 2009:481031.
26. Cole N.B., Murphy D.D. The cell biology of alpha-synuclein: a sticky problem?. Neuromol Med 2002, 1:95-109.
27. Modi G., Pillay V., Yahya E. Choonara Advances in the treatment of neurodegenerative disorders employing nanotechnology. Ann NY Acad Sci 2010, 1184:154-172.
28. Trapani A., De Giglio E., Cafagna D., et al. Characterization and evaluation of chitosan nanoparticles for dopamine brain delivery. Int J Pharm 2011, 419:296-307.
29. Huang R., Ke W., Liu Y., et al. Gene therapy using lactoferrin-modified nanoparticles in a rotenone-induced chronic Parkinson model. J Neurol Sci 2010, 290:123-130.
30. 2 nanotube arrays for the detection of α-synuclein. Chemistry 2010, 16:14439-14446.
31. Yu J., Lyubchenko Y.L. Early stages for Parkinson's development: alpha-synuclein misfolding and aggregation. J Neuroimmune Pharmacol 2009, 4:10-16.
32. Baron R., Zayats M., Willner I. Dopamine-, L-DOPA-, adrenaline-, and noradrenaline-induced growth of Au nanoparticles: assays for the detection of neurotransmitters and of tyrosinase activity. Anal Chem 2005, 77:1566-1571.
33. Norrby E. Prions and protein-folding diseases. J Intern Med 2011, 270:1-14.
34. Lim Y.B., Mays C.E., Kim Y., Titlow W.B., Ryou C. The inhibition of prions through blocking prion conversion by permanently charged branched polyamines of low cytotoxicity. Biomaterials 2010, 31:2025-2033.
35. Ai Tran H.N., Sousa F., Moda F., et al. A novel class of potential prion drugs: preliminary in vitro and in vivo data for multilayer coated Au nanoparticles. Nanoscale 2010, 2:2724-2732.
36. Sousa F., Mandal S., Garrovo C., et al. Functionalized Au nanoparticles: a detailed in vivo multimodal microscopic brain distribution study. Nanoscale 2010, 2:2826-2834.
37. Xiao S.J., Hu P.P., Wu X.D., et al. Sensitive discrimination and detection of prion disease-associated isoform with a dual-aptamer strategy by developing a sandwich structure of magnetic microparticles and quantum dots. Anal Chem 2010, 82:9736-9742.
38. Xie M., Luo K., Huang B.H., et al. PEG-interspersed nitrilotriacetic acid-functionalized quantum dots for site-specific labeling of prion proteins expressed on cell surfaces. Biomaterials 2010, 31:8362-8370.
39. Kiernan M.C., Vucic S., Cheah B.C., et al. Amyotrophic lateral sclerosis. Lancet 2011, 377:942-955.
40. Bondì M.L., Craparo E.F., Giammona G., Drago F. Brain-targeted solid lipid nanoparticles containing riluzole: preparation, characterization and biodistribution. Nanomedicine-UK 2010, 5:25-32.
41. Bataveljić D., Stamenković S., Bačić G., Andjus P.R. Imaging cellular markers of neuroinflammation in the brain of the rat model of amyotrophic lateral sclerosis. Acta Physiol Hung 2011, 98:27-31.
42. Machtoub L., Bataveljić D., Andjus P.R. Molecular imaging of brain lipid environment of lymphocytes in amyotrophic lateral sclerosis using magnetic resonance imaging and SECARS microscopy. Physiol Res 2011, 60(Suppl. 1):S121-S127.
43. Cho Y, Borgens RB. Polymer and nano-technology applications for repair and reconstruction of the central nervous system. Exp Neurol, 2011, in press.
44. Ali S.S., Hardt J.I., Quick K.L., et al. A biologically effective fullerene (C60) derivative with superoxide dismutase mimetic properties. Free Radic Biol Med 2004, 37:1191-1202.
45. Das M., Patil S., Bhargava N., et al. Auto-catalytic ceria nanoparticles offer neuroprotection to adult rat spinal cord neurons. Biomaterials 2007, 28:1918-1925.
46. Jin G.Z., Kim M., Shin U.S., Kim H.W. Neurite outgrowth of dorsal root ganglia neurons is enhanced on aligned nanofibrous biopolymer scaffold with carbon nanotube coating. Neurosci Lett 2011, 501:10-14.
47. Liu J.J., Wang C.Y., Wang J.G., Ruan H.J., Fan C.Y. Peripheral nerve regeneration using composite poly(lactic acid-caprolactone)/nerve growth factor conduits prepared by coaxial electrospinning. J Biomed Mater Res A 2011, 96:13-20.
48. Prabhakaran M.P., Ghasemi-Mobarakeh L., Ramakrishna S. Electrospun composite nanofibers for tissue regeneration. J Nanosci Nanotechnol 2011, 11:3039-3057.
49. Lee J, Bashur C, Milroy C, Forciniti L, Austein A, Schmidt C. Nerve growth factor-immobilized electrically conducting fibrous scaffolds for potential use in neural engineering applications. IEEE Trans Nanobiosci, 2011, in press.
50. Mahmoudi M., Laurent S., Shokrgozar M.A., Hosseinkhani M. Toxicity evaluations of superparamagnetic iron oxide nanoparticles: cell "vision" versus physicochemical properties of nanoparticles. ACS Nano 2011, 5:7263-7276.
51. Hutter E., Boridy S., Labrecque S., et al. Microglial response to gold nanoparticles. ACS Nano 2010, 4:2595-2606.
52. Wang J., Sun P., Bao Y., Liu J., An L. Cytotoxicity of single-walled carbon nanotubes on PC12 cells. Toxicol In Vitro 2011, 25:242-250.
53. 2 particles exert size and surface coating dependent retention and lesions on the murine brain. Toxicol Lett 2011, 207:73-81.
54. Win-Shwe T.T., Fujimaki H. Nanoparticles and neurotoxicity. Int J Mol Sci 2011, 12:6267-6280.